Communiqués Rapport Therapeutics, Inc.

Actions

RAPP

US75383L1026

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 16:50:07 06/08/2026			Varia. 5j.	Varia. 1 janv.
44,34 ^USD	+4,49%		+3,99%	+46,62%

05/08	Rapport Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
28/07	RAPPORT THERAPEUTICS, INC. : William Blair & Co. persiste à l'achat	ZM

Communiqués

05/08	Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update	GL
20/05	Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference	GL
07/05	Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update	GL
07/05	Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update	AQ
21/04	Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting	GL
01/04	Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting	GL
10/03	Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	GL
09/03	Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China	GL
24/02	Rapport Therapeutics to Participate in Upcoming Investor Conferences	GL
07/01	Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline	GL
18/12	Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	GL
05/12	Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures	GL
25/11	Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting	GL
25/11	Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting	AQ
06/11	Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update	GL
06/11	Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update	AQ
05/11	Rapport Therapeutics to Participate in Upcoming Investor Conferences	GL
11/09/25	Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit	GL
11/09/25	Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit	AQ
10/09/25	Rapport Announces Pricing of Public Offering of Common Stock	GL
08/09/25	Rapport Announces Proposed Public Offering of Common Stock	GL
08/09/25	Rapport Announces Proposed Public Offering of Common Stock	AQ
08/09/25	Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures	GL
08/09/25	Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures	AQ
05/09/25	Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025	GL